ClinicalTrials.Veeva

Find clinical trials for Non-Small-Cell Lung Cancer in Cincinnati, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Triple Negative Breast Cancer
Colorectal Cancer

Non-Small-Cell Lung Cancer trials near Cincinnati, OH, USA:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Cincinnati, Ohio, United States and 43 other locations

Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer (EDGE-Lung)

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: Platinum-Based Doublet
Drug: Domvanalimab

Phase 2

Arcus Biosciences
Arcus Biosciences

Kettering, Ohio, United States and 23 other locations

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

NSCLC comprises of approximately 84 percent (%) of all lung cancers and is often diagnosed at advanced stage due to poor prognosis....

Active, not recruiting
Lung Cancer, Non-Small Cell
Drug: Chemotherapy
Drug: Dostarlimab

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Cincinnati, Ohio, United States and 57 other locations

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)

A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: MEDI4736

Phase 2

AstraZeneca
AstraZeneca

Blue Ash, Ohio, United States and 137 other locations

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC)....

Active, not recruiting
Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Drug: Pemetrexed
Drug: Paclitaxel

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Cincinnati, Ohio, United States and 126 other locations

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC)....

Enrolling
Stage III Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Biological: IOV-4001

Phase 1, Phase 2

Iovance Biotherapeutics

Cincinnati, Ohio, United States and 7 other locations

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The ...

Enrolling
Non-small Cell Lung Cancer
Drug: Pembrolizumab (MK-3475) 200 mg
Device: NovoTTF-200T

Phase 2

NovoCure
NovoCure

Edgewood, Kentucky, United States and 23 other locations

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously...

Active, not recruiting
Advanced Non Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Drug: Docetaxel
Drug: MRTX849

Phase 3

Mirati Therapeutics
Mirati Therapeutics

Kettering, Ohio, United States and 227 other locations

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02)

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy ...

Enrolling
Metastatic Non-small Cell Lung Cancer
Drug: Paclitaxel
Drug: Pembrolizumab

Phase 3

AstraZeneca
AstraZeneca

Dayton, Ohio, United States and 225 other locations

Locations recently updated

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Ca...

Enrolling
Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Drug: furmonertinib 240 mg oral, daily
Drug: furmonertinib 160 mg oral, daily

Phase 3

ArriVent BioPharma
ArriVent BioPharma

Cincinnati, Ohio, United States and 197 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems